CD274 and non-small cell lung carcinoma: Most notably, the KEYNOTE-042 trial initially showed NSCLC patients with any positive PD-L1 IHC staining (≥1% TPS) had a survival advantage for frontline pembrolizumab over chemotherapy (16.7 vs. 12.1 months), followed by the FDA’s lowering of the cutoff from ≥50% TPS to ≥1% TPS on the label indication.